How much funding has Architect Therapeutics raised?

Architect Therapeutics has raised $120.0M in total funding, most recently a Series B round.

Who are Architect Therapeutics's investors?

Architect Therapeutics's investors include OrbiMed, ARCH Venture Partners, Frazier Healthcare, Viking Global.

When was Architect Therapeutics founded?

Architect Therapeutics was founded in 2023.

Where is Architect Therapeutics headquartered?

Architect Therapeutics is headquartered in San Diego, California, United States.

What industry is Architect Therapeutics in?

Architect Therapeutics operates in Biotech, Healthcare.

How many employees does Architect Therapeutics have?

Architect Therapeutics has 11-50 employees.

Architect Therapeutics

C-H activation to design and synthesize novel 3D scaffolds

San Diego, United States · Founded 2023 · $120.0M raised

Biotech

Healthcare

Headquarters: San Diego, California
Employees: 11–50
Founded: 2023
Business Model: B2B

Website: architecttherapeutics.com
Total Funding: $120.0M
Last Round: $120.0M Series BJan 2024
Rounds: 3

About

Architect Therapeutics is a San Diego biopharmaceutical company leveraging C-H bond activation chemistry pioneered by founder Jin-Quan Yu to design novel 3D small molecule drug architectures. The platform integrates covalent and non-covalent drug discovery approaches with proprietary libraries and advanced screening to pursue first- and best-in-class therapies in immunology and oncology.

Summary

Architect Therapeutics is a Biotech company based in San Diego, United States, founded in 2023. It has raised $120.0M in total across 3 rounds, most recently a $120.0M Series B round in Jan 2024. Investors include OrbiMed, ARCH Venture Partners and Frazier Healthcare.